News Releases

Date	Title and Summary	View
May 06, 2021	JOHNSON & JOHNSON VISION ANNOUNCES THE APPROVAL OF TECNIS SYNERGY™ AND TECNIS SYNERGY™ TORIC II IOLS IN THE U.S. AND TECNIS SYNERGY™ TORIC II IOLS IN CANADA
May 03, 2021	Johnson & Johnson to Participate in Bernstein’s 37th Annual Strategic Decisions Virtual Conference
Apr 30, 2021	Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of BCMA CAR-T Therapy Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed and/or Refractory Multiple Myeloma
Apr 23, 2021	Johnson & Johnson Single-Shot COVID-19 Vaccinations to Resume in the U.S. for All Adults Aged 18 and Older Following CDC and FDA Decision Important information for healthcare providers and the public included in updated FDA Emergency Use Authorization Fact Sheets NEW BRUNSWICK, N.J. , April 23, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced that vaccinations with the Company's COVID-19 single-shot
Apr 23, 2021	New Phase 3 Data Showed First-in-Class TREMFYA® (guselkumab) Provided Durable Complete Skin Clearance Through Five Years in Moderate to Severe Plaque Psoriasis (PsO) and Robust Joint Symptom Improvement Through 52 Weeks in Active Psoriatic Arthritis (PsA)
Apr 20, 2021	Johnson & Johnson COVID-19 Vaccine Roll-out to Resume in Europe Following European Medicines Agency (EMA) Review EMA Confirms Overall Benefit-Risk Profile Remains Positive Company to update the COVID-19 Vaccine Janssen Summary of Product Characteristics and Package Leaflet to include important information on very rare adverse event Johnson & Johnson remains committed to supplying 200 million doses of its
Apr 20, 2021	Johnson & Johnson Announces Dividend Increase of 5.0% NEW BRUNSWICK, N.J. , April 20, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a 5.0% increase in the quarterly dividend, from $1.01 per share to $1.06 per share. "Despite a year of unprecedented disruption, Johnson & Johnson
Apr 20, 2021	Johnson & Johnson Reports 2021 First-Quarter Results: - 2021 First Quarter Sales of $22.3 Billion reflecting strong growth of 7.9%, operational growth of 5.5%* and adjusted operational growth of 6.0%* - 2021 First Quarter EPS of $2.32 increased 6.9%; adjusted EPS of $2.59 increased 12.6%* - Company increased 2021 Full-Year guidance for adjusted
Apr 19, 2021	Janssen Provides Update on Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ERLEADA® (apalutamide) and ZYTIGA® (abiraterone acetate) Plus Prednisone Combination
Apr 19, 2021	DARZALEX® SC Becomes the First and Only Health Canada-Approved Treatment for Patients with Newly Diagnosed Light Chain (AL) Amyloidosis, A Rare Disease